23 November 2017

Recently awarded to Elke de Jong, department of Dermatology, and collegues.

Elke de Jong and Juul van den Reek recently received a grant from the National Psoriasis Foundation (USA) to investigate biomarkers for prediction of biological therapy response in patients with psoriasis.

Elke de Jong and Joost Schalkwijk received, in collaboration with the Sint Maartenskliniek  (Mark Wenink, Elien Mahler) and the department of medical immunology Radboudumc (Hans Koenen),  a grant from the Radboudumc regional PhD fund for the  research proposal “From psoriasis to arthritis: Improved Detection, characterization and Early treatment of Psoriatic Arthritis (IDE-PsA)” .

In 2016 the department started a study to investigate the dose decrease of biologics for psoriasis, supported by Zonmw (Elke de Jong, Juul van den Reek, Wietske Kievit). In October 2017, Elke de Jong was awarded a grant to implement these results in the Radboudumc by the VGZ ‘Betaald Beter’ project. 

Related news items

Large NWA ORC grant awarded for national skin research: Next Generation ImmunoDermatology

23 March 2022 Research for better treatment methods for chronic skin diseases. read more

VWS report on AI and describes added value of MonitAir app

1 February 2022 The report Social costs and benefits of Artificial Intelligence in healthcare from the Dutch Ministry of Health, Welfare and Sport was published. The researchers were positive about the smart app MonitAir, which was partly developed by Primary and Community Care of the Radboudumc. read more

Radboudumc does large-scale research on systemic sclerosis

10 September 2020 In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases. read more

Tight controlled dose reduction of biologics in psoriasis patients

7 May 2020 Published in JAMA Dermatology, RIHS researcher Selma Atalay and colleagues investigated in a randomized controlled trial a tight controlled dose reduction strategy of the biologics adalimumab, etanercept and ustekinumab in psoriasis patients. read more

First BeNeFit funding granted for psoriasis

17 January 2020 RIHS researchers Elke de Jong and Juul van den Reek of Dermatology Radboudumc and Dermatology Ghent received a grant of 1.6 million euros for investigating dose reduction of the newest biologics for psoriasis. read more

New drugs available more quickly for the right patient

12 January 2017 Wietske Kievit and Floor Berden have illustrated this in PlosOne paper read more